

## BIBLIOGRAPHY

### Deleterious Effects of Epstein-Barr Virus Reactivation and Autoimmunity on CNS Pain Control Mechanisms

1. Anderson D, Fanberge I, Hedstrom AK. Treatment options for Epstein-Barr virus related disorders of the central nervous system. *Infect and Drug Resist* 2023;16:4599-4620.
2. Apkarian AV, Sosa Y, Sont S, et al. Chronic back pain is associated with decreased prefrontal and thalamic gray matter density. *J Neurosci* 2004;24:10410-10415.
3. Bjornevik K, Cortese M, Healy BC, et al, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. *Science* 2022;375:296-301.
4. Buckalew N, Haut MW, Morrow L, et al. Chronic pain is associated with brain volume loss in older adults: preliminary evidence. *Pain Med* 2008;9:240-248.
5. Cauda F, Palerno S, Costa T, et al. Gray matter alterations in chronic pain: a network-oriented meta-analytic approach. *Neuroimage Clin* 2014;16:676-685.
6. Duan Y, et al. Immune cell infiltration and the genes associated with ligamentum flavum hypertrophy: identification and validation. *Front Cell Dev Biol* 2022;10:91478.
7. Harley JB, Chan X, Pujato M, et a. Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity. *Nat Genet* 2018;50:699-707.
8. Harrow T. Epstein-Barr virus could be a cause of multiple autoimmune disorders. *VA Research Currents* April 18, 2018.
9. Houen G, Trier NH. Epstein-Barr virus and systemic autoimmune disease. *Front Immunol* 2020;11:1-13.
10. Hsu D, Malefytro W, Fiorentino DF, et al. Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF 1. *Science* 1990;250:830-832.
11. Indari O, Tiwari D, Tanwar M, et al. Early biomolecular changes in brain microvascular endothelial cells under Epstein-Barr virus influence: A Raman microspectroscopic investigation. *Integr Biol* 2022;14:89-97.
12. Indari O, Jakhomola S, Pathak DK, et al. Comparative account of biomolecular changes post Epstein Barr virus infection of the neuronal and glial cells using Raman microspectroscopy. *ACS Chem Neurosci* 2022;13:1627-1637.
13. Jakhmola S, Jha HM. Glial cell response to Epstein Barr Virus infection: a plausible contribution to virus-associated inflammatory reactions in the brain. *Virology* 2021;559:182-195.
14. Hsu D, Malefytro W, Fiorentino DF, et al. Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF 1. *Science* 1990;250:830-832.
15. Jha HC, Pei Y, Robertson ES. Epstein-Barr virus: disease linked to infection and transformation. *Front Microbiol* 2016;7:1-16.
16. Jones KJ. Gonadal steroids and neuronal regeneration: a therapeutic role. *Adv Neurol* 1993;59:227-240.
17. Kiefer R, Kreutzberg GW. Effects of dexamethasone on microglial activation in vitro. *J Neuroimmunology* 1991;34:99-108.
18. Kiguchi N, et al. Chemokines and cytokines in neuroinflammation leading to neuropathic pain. *Curr Opin Pharmacol* 2012;12:55-61.
19. Li YL, Wang JY, Lil K, et al. Epstein-Barr virus to be a trigger of autoimmune glial fibrillary acidic protein astrocytopathy. *CNS Neurosci Ther* 2023;29:4139-4146.

20. Libert N, Bigailon C, Chargari C, et al. Epstein-Barr virus reactivation in critically ill immunocompetent patients. *Biomed J* 2015;38:70-76.
21. Maier A, Kapfenberger R, Katano I, et al. Nonregional small fiber neuropathy in cases of autoimmune autonomic neuropathy. *J Neurol* 2022;269:6648-6654.
22. Meisel C, Schwab JM, Prass K, et al. Central nervous system injury-induced immune deficiency syndrome. *Nat Rev Neurosci* 2005;6:775-786.
23. Mika J, Zychowska M, Popiolek-Barczy K, et al. Importance of glial activation in neuropathic pain. *Eur J Pharmacol* 2013;716:106-119.
24. Milligan ED, Watkins LR. Pathological and protective roles of glia in chronic pain. *Nat Rev Neurosci* 2009;10:23- 36.
25. Nagata K, Hayashi K. Epstein-Barr virus reactivation-induced immunoglobulin production: significance on autoimmunity. *Microorganisms* 2020;8:1875-1890.
26. Ngou J, Graafland H, Segondy M. Antibodies against polypeptides of purified Epstein-Barr virus in serum from patients with connective tissue diseases. *J Autoimmun* 1992;5:243-249.
27. Rhodes G, Pumpold H, Kurki P, et al. Autoantibodies in infectious mononucleosis have specificity for the glycine-alanine repeating region of the Epstein-Barr virus nuclear antigen. *J Exp Med* 1987;165:1026-1040.
28. Rodriguez-Raecke R, Niemeier A, Ihler K, et al. Brain gray matter decrease in chronic pain is the consequence and not the cause of pain. *J Neurosci* 2009;29:13746-13750.
29. Romundstad L, Breivik A, Niemi G, et al. Methylprednisolone intravenously 1 day after surgery has sustained analgesic and opioid-sparing effects. *Acta Anaesthesiol Scand* 2004;48:1223-1231.
30. Seminowicz DA, Labus JS, Bueller JA, et al. Regional gray matter density changes in brains of patients with irritable bowel syndrome. *Gastroenterology* 2010;139:48-57.
31. Seminowicz DA, Wideman TH, Naso L, et al. Effective treatment of chronic low back pain in humans reverses abnormal brain anatomy and function. *J Neuroscience* 2011;31:7540-7550.
32. Soni N, Ora R, Sing P, et al. Unpacking the CNS manifestations of Epstein-Barr virus: an imaging perspective. *Amer J Neurorad* 2023;44:1002-1008.
33. Sotgin ML, Riella G, Formaglio F, et al. Central effort of ketorolac involving NMDA receptors activity. *Brain Res* 1998;223-226
34. Stubhaug A, Romundstad L, Kaasa T, et al. Methylprednisolone and ketorolac rapidly reduce hyperalgesia around a skin burn injury and increase pressure pain thresholds. *Acta Anaesth Scand* 2007;51:1138-1146.
35. Sumaya, CV. Endogenous reactivation of Epstein-Barr virus infection. *J Infect Dis* 1977;135:374-379.
36. Sunderson B, Shirafkan F, Ripperger K, et al. The role of viral infections in the onset of autoimmune diseases. *Viruses* 2023;15:782-814.
37. Sutton RN, Emond RT, Thomas DB, et al. The occurrence of autoantibodies in infectious mononucleosis. *Clin Exp Immunol* 1974;17:427-436.
38. Takedo K, Sawamura S, Sekiyama H, et al. Effect of methylprednisolone on neuropathic pain and spinal glial activation in rats. *Anesthesiology* 2004;100:1249-1257.
39. Teitelbaum J. Effective treatment for chronic fatigue syndrome and fibromyalgia: an overview and 35 treatments for tough cases. *Townsend Letter* Nov, 2015:56-59.
40. Thompson SJ, Pitcher MH, Stone LS, et al. Chronic neuropathic pain reduces opioid receptor availability with associated anhedonia in rat. *Pain* 2018;159:1856-1866.

41. Tiwari D, Mittal N. Unraveling the links between neurodegeneration and Epstein-Barr virus-mediated cell cycle dysregulation. *Curr Res Neurobiol* 2023;3:2665-2945.
42. Vaughn JH. The Epstein-Barr virus in autoimmunity. *Springer Semin Immunopathol* 1995;17:203-230.
43. Watkins LR, Hutchinson MR, Ledeboer H, et al. Glia as the "bad guys": implications for improving clinical pain control and the utility of opioids. *Brain Behav Immun* 2007;21:131-146.
44. Watkins LR, Maier SF. Beyond neurons: evidence that immune and glial cells contribute to pathologic pain states. *Physiol Rev* 2002;82:981-1011.
45. Wood PB, Glabus MF, Simpson R, et al. Changes in gray matter density in fibromyalgia: correlation with dopamine metabolism. *J Pain* 2009;10:609-618.
46. Werner MY, Lassen B, Kehlet H. Analgesic effects of dexamethasone in burn injury. *Reg Anesth Pain Med* 2002;27:254-260.
47. Zang Y, Chee A, Shi P, et al. Intervertebral disc cells produce interleukins found in patients with back pain. *Am J Phys Med* 2016;95:407-415.
48. Zhang N, Zou Y, Jiang L, et al. Epstein Barr virus and neurologic diseases. *Front Mol Biosci* 2022;10:1-34.